The new fund will mostly support biotechs making new drugs, with investments spanning from initial financings to follow-on ...

Now in a tug of war with Lundbeck, Alkermes could either lose out on a marketed sleepiness drug or end up paying ...

The alliance extends a deal streak in genetic medicine for Lilly and hands the company rights to an experimental treatment ...

After multiple clinical setbacks and layoff rounds, Mersana accepted an offer in which the bulk of the payouts will only ...

The drug appears effective against both “relapsing” and “primary progressive” forms of the disease, though some analysts ...

Korro’s lead program for alpha-1 antitrypsin deficiency wasn’t as potent as anticipated, leading the company to change course ...

The decision, issued without the input of an official advisory committee, revises long-held labeling on the drugs cautioning ...

The treatment — which could be the first novel antimalarial in decades — showed the ability in testing to combat drug ...

Pfizer quickly consummated the $10 billion buyout after one-upping Novo Nordisk. Elsewhere, Lundbeck submitted a rival offer for Avadel Pharmaceuticals and Zealand Pharma dropped an obesity drug.

Metagenomi is laying of 25% of its staff while switching up leadership. Elsewhere, Ovid announced a CEO succession plan and Cogent Biosciences and Galecto saw their shares skyrocket.

The deal, one of two multibillion-dollar buyouts from Merck this year, centers around a drug that could become an alternative ...

Milvexian’s failure in acute coronary syndrome dampens the outlook for other anticoagulants like it and is the latest in a ...